权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Synthetic Chemical Biology Core

合成化学生物学核心

基本信息

批准号：
10414318
负责人：
Jon A Tunge
金额：
$ 22.95万
依托单位：
UNIVERSITY OF KANSAS LAWRENCE
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-07-01 至 2027-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10414318
关键词：
Address Affinity Benchmarking Biological Biology Biomedical Research Biotin Centers of Research Excellence Chemicals Chemistry Client Collection Communicable Diseases Communities Core Facility Custom DNA Sequencing Facility Development Discipline Disease Pathway Evaluation Faculty Fluorescent Probes Funding Generations Genes Goals Imaging Device In Vitro Isotopes Kansas Lead Mission Molecular Analysis Molecular Probes Organic Chemistry Pathology Pathway interactions Peptides Pharmaceutical Chemistry Pharmacology Phase Physiology Pilot Projects Property Proteins Research Research Infrastructure Research Personnel Services Synthesis Chemistry Techniques Therapeutic Validation Work base biological systems design drug development drug discovery fluorophore genome sequencing in vitro Bioassay in vivo in vivo imaging innovation interest nanofabrication novel outreach preclinical study programs screening small molecule success tool

项目摘要

PROJECT SUMMARY – CORE C The Synthetic Chemical Biology Core (SCB) was established in July 2016 from the merger of the Center for Molecular Analysis of Disease Pathways (CMADP) Molecular Probes Core with the newly established Chemical Biology of Infectious Disease (CBID) Medicinal Chemistry Core. The synthetic capabilities of the SCB will fulfill the specific aims of both COBRE centers. The mission for the SCB in Phase 3 is to provide CMADP-affiliated junior faculty, as well as other investigators in the state of Kansas, with novel molecular probes as pharmacological tools for in vitro or in vivo elucidation of particular pathways. The SCB will also work towards achieving self-sustainability beyond Phase 3. The Core will offer expert design and synthesis of small molecule and peptide molecular probes, with an emphasis on the generation of fluorescent and other affinity tagged molecules. The SCB will function synergistically with other CMADP-funded Core facilities, including the Genome Sequencing Core, to identify genes that impact functions of probes in vivo, and the KU Nanofabrication Facility, to develop devices for imaging and chemical analysis. This integration is designed to empower faculty to use chemical biology approaches to investigate biological problems. The specific aims that will be addressed by the SCB in Phase 3 are: (1) Provide enabling small molecules of interest to COBRE investigators and other clients; (2) Provide synthesis of conventional and specialized peptides to investigators; (3) Provide outreach, administrative, and fiscal support necessary to manage the above activities both in the context of COBRE projects and to offer services to the larger Kansas research community (4) To continue developing a critical mass of core lab users so that the facility becomes a self-sustaining, integral part of the biomedical research infrastructure in the state of Kansas.

项目概要-核心C 合成化学生物学核心（SCB）成立于2016年7月，由中心合并为疾病途径的分子分析（CMADP）分子探针核心与新建立的化学传染病生物学（CBID）药物化学核心。SCB的合成能力将满足两个COBRE中心的具体目标。SCB在第三阶段的使命是提供CMADP附属的初级教师，以及其他研究人员在堪萨斯州，与新的分子探针，用于体外或体内阐明特定途径的药理学工具。SCB还将致力于实现第三阶段之后的自我可持续性。核心将提供专家设计和合成的小分子和肽分子探针，重点是产生荧光和其他亲和标记分子。SCB将与其他CMADP资助的核心设施协同运作，包括基因组测序核心，以确定影响体内探针功能的基因，和KU纳米工厂，来开发成像和化学分析的设备。这种整合旨在使教师能够使用用化学生物学方法研究生物学问题。 SCB在第三阶段将解决的具体目标是：（1）提供使能的小分子， COBRE研究人员和其他客户的兴趣;（2）提供常规和专业肽的合成（3）提供必要的外联、行政和财政支持，以管理上述活动; 在COBRE项目的背景下开展活动，并为更大的堪萨斯研究社区提供服务 (4)继续发展核心实验室用户的临界质量，使该设施成为一个自我维持的，是堪萨斯州生物医学研究基础设施的一部分。